TIZIMLI QIZIL YUGURIKDA INTERFERON-STIMULLANGAN GENLAR MUTATSIYASI HAMDA ULARNING KLINIK-MOLEKULYAR GENETIK ASOSLARI.
DOI:
https://doi.org/10.5281/zenodo.17706267Keywords:
Tizimli qizil yugurik, interferon, T-limfotsit yoki T-hujayra, avtoimmunitet, sitokinlar, anifrolumab, sifalimumab, rontalizumab.Abstract
So‘nggi yillarda tug‘ma va orttirilgan immunitetning molekulyar asoslarini chuqurroq o‘rganish natijasida ushbu interferonlarning autoimmun kasalliklardagi roli qayta ko‘rib chiqildi. Bugungi kunga kelib, interferon tomonidan tartibga solinadigan ko‘plab genlar — “interferon imzosi genlari” (IFN signature genes) aniqlangan. Ushbu genlarning ekspressiyasi tizimli qizil yugurik (TQY) bilan kasallangan bemorlarda sezilarli darajada ortgani aniqlangan, bu esa I tip va III tip interferonlarning TQY patogenezidagi muhim rolini ko‘rsatadi.
References
Crow MK. Type I interferon in the pathogenesis of lupus. J Immunol. 2014;192(12):5459–5468. doi:10.4049/jimmunol.1002795
Khamashta M, et al. Anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211–221. doi:10.1056/NEJMoa1912196
Niewold TB. Interferon alpha as a primary pathogenic factor in human lupus. J Interferon Cytokine Res. 2011;31(12):887–892.
Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019;393(10188):2344–2358. doi:10.1016/S0140-6736(19)30546-X.
Morand EF, et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med. 2020;382(3):211–221. [DOI:10.1056/NEJMoa1912196]
Figueiredo-Braga M, et al. IL-17 and IFN pathways in systemic lupus erythematosus: convergence and therapeutic implications. Autoimmun Rev. 2022;21(9):103154. [DOI:10.1016/j.autrev.2022.103154]
Rodríguez-Carrio J et al. Th17 responses and IL-23/IL-17 axis in lupus nephritis. Rheumatology. 2020;59(9):2461-2470. doi:10.1093/rheumatology/keaa078
